Iovance Biotherapeutics (IOVA) Set to Announce Earnings on Thursday

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 1,343.27% and a negative return on equity of 65.04%. The firm had revenue of $31.11 million during the quarter, compared to analysts' expectations of $24.59 million. During the same period in the previous year, the company earned ($0.47) EPS. The firm's revenue for the quarter was up 12969.7% compared to the same quarter last year. On average, analysts expect Iovance Biotherapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Iovance Biotherapeutics Trading Up 7.2 %

Shares of IOVA stock traded up $0.75 during trading hours on Friday, reaching $11.19. 5,301,491 shares of the stock were exchanged, compared to its average volume of 7,120,401. The firm has a market capitalization of $3.13 billion, a price-to-earnings ratio of -6.70 and a beta of 0.62. Iovance Biotherapeutics has a 12-month low of $3.76 and a 12-month high of $18.33. The company's 50-day moving average price is $10.20 and its 200-day moving average price is $9.84.

Analysts Set New Price Targets

Several equities research analysts have recently commented on IOVA shares. StockNews.com upgraded shares of Iovance Biotherapeutics to a "sell" rating in a report on Monday, August 12th. UBS Group started coverage on shares of Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $17.00 price target for the company. HC Wainwright restated a "buy" rating and issued a $32.00 price target on shares of Iovance Biotherapeutics in a report on Monday, August 12th. Finally, Piper Sandler lowered shares of Iovance Biotherapeutics from an "overweight" rating to a "neutral" rating and reduced their price target for the company from $19.00 to $10.00 in a report on Monday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Iovance Biotherapeutics has an average rating of "Moderate Buy" and an average price target of $22.33.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.